Redcare Pharmacy N.V. (SAE1.F,RDC.DE) Monday raised its full-year 2026 guidance after reporting stronger-than-expected trading during the first two months of the second quarter, driven by accelerating growth in both prescription (Rx) and non-prescription (non-Rx) sales.
The online pharmacy operator said group revenue increased 20% year-over-year quarter-to-date, with growth accelerating compared with the first quarter of 2026. The DACH segment, comprising Germany, Austria and Switzerland, posted 21% revenue growth, supported by stronger non-Rx sales and continued momentum in prescription medicines.
In Germany, non-Rx growth accelerated to 14% year-over-year during the first two months of the quarter, compared with 9% growth in the first quarter. Total Rx sales increased 33%, while German Rx revenue surged 57%, up from 55% growth recorded in the first quarter.
The International segment maintained solid momentum, with revenue increasing 16% in April and May, matching the growth rate achieved in the first quarter.
The company also raised its German Rx revenue forecast to 680 million euros to 720 million euros, representing growth of 35% to 43%, and now expects an adjusted EBITDA margin of 2.5% to 3.0%, compared with its previous target of more than 2.5%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.